Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab with RVD in Newly Diagnosed Multiple Myeloma
NCT02375555Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2015
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by Dana-Farber Cancer Institute. Started May 2015; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02375555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375555.